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http://dx.doi.org/10.1016/j.pedneo.2Background: The aim of this study was to investigate glucose 6-phosphate dehydrogenase
(G6PD) activity in term and late preterm babies with severe neonatal hyperbilirubinemia
and its relationship to the severity and treatment of this disorder, regardless of level of
G6PD activity (deficient/normal).
Methods: A total of 529 term and late preterm (35 weeks) infants (228 female, 301 male) who
were diagnosed with severe hyperbilirubinemia were included in this study. In each case,
serum was collected to evaluate blood group, direct Coombs’ test, complete blood cell count,
total and direct bilirubin, thyroid-stimulating hormone, and G6PD activity. A partial correlation
analysis was carried out to assess the relationship between G6PD activity and total bilirubin
levels.
Results: A significant correlation was found between the severity of hyperbilirubinemia and
G6PD activity in both males and females. Male neonates who had G6PD levels <12 U/g Hb
required more phototherapy time than neonates who had G6PD levels 12 U/g Hb; and female
neonates who had G6PD levels <16 U/g Hb required more phototherapy time than neonates
who had G6PD levels 16 U/g Hb (p < 0.0001). When we analyzed only breastfed infants, a
significant difference also emerged in both sexes. Decreased G6PD activity was associated with
increased phototherapy time and the need for exchange transfusion.
Conclusion: Routine checks of G6PD level in hyperbilirubinemic neonates are very important in
providing proper medical management to prevent bilirubin-induced neurological dysfunction.dem Hastanesi, Cumhuriyet Caddesi, Number 66, 01130 Seyhan, Adana, Turkey.
net.com (H. Kilicdag).
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G6PD activity and neonatal hyperbilirubinemia 203Appropriate identification of G6PD (<12 U/g Hb for male infants and <16 U/g Hb for female
infants) raises awareness of the severity of the condition and the necessity for immediate care
of severe hyperbilirubinemic infants.
Copyright ª 2013, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
The glucose-6-phosphate dehydrogenase (G6PD), which
exists in every cell of the body, protects cell proteins from
oxidative damage.1,2 To control oxidative stress, G6PD
converts nicotinamide adenine dinucleotide phosphate
(NADP) into reduced nicotinamide adenine dinucleotide
phosphate (NADPH) by the hexose monophosphate
pathway. This pathway is the only source of NADPH in
erythrocytes, and it is an important cofactor of glutathione
metabolism. Hemolysis related to glutathione metabolism
is a common problem that stems from G6PD deficiency.3e5
G6PD deficiency, a very prevalent syndrome that affects
an estimated 400 million people worldwide,6 is an X-linked
genetic defect that can cause hemolytic crisis or severe
neonatal hyperbilirubinemia, which can lead to bilirubin
encephalopathy and kernicterus.7e10
Neonatal hyperbilirubinemia is the result of an imbal-
ance between the production and conjugation of bilirubin.
Acute hemolysis, which leads to an increase in bilirubin,
plays a relatively minor role in most cases of G6PD-
associated neonatal hyperbilirubinemia. Decreased bili-
rubin conjugation with promoter polymorphism for the
gene for the bilirubin-conjugating enzyme, uridine 50-
diphospho-glucuronoslytransferase 1A1, seems to be the
major factor.11e13
During the neonatal period, oxidative stress is high and
antioxidative functions are insufficient.14,15 The NADPH
level in erythrocytes is directly related to G6PD levels.1,2 In
babies at this precise physiological period, G6PD levels
could be more consequential in terms of the antioxidative
defense of erythrocytes. Therefore, even with normal
levels of G6PD, lower enzyme activity might be the cause of
the increased vulnerability to oxidative stress, which could
increase the severity of hyperbilirubinemia.
We believe that only one cut-off level is not appropriate
to explain the relationship between G6PD activity and
hyperbilirubinemia. Thus, we hypothesized that in severe
hyperbilirubinemic infants, G6PD levels have an important
effect on the severity of the disease. Therefore, in this
study, we investigated G6PD activity in term and late pre-
term babies who were admitted to a neonatal intensive
care unit (NICU) due to severe neonatal hyperbilirubinemia
and its relationship with the severity and treatment of this
disorder, without separating G6PD as deficient or normal.
2. Methods
This prospective study was conducted between March 2002
and August 2007 at the Neonatology Department of Baskent
University Hospital, Ankara, Turkey. The study protocol
was approved by the institutional review board of theuniversity. During this research period, 5300 babies were
born at Baskent University, and 693 (299 females, 394
males) were diagnosed with severe hyperbilirubinemia. Of
these, 45.5% were inborn, and the rest were all outborn.
Phototherapy and exchange transfusion were performed
according to the American Academy of Pediatrics (AAP)
clinical practice guidelines.16,17 The need for phototherapy
and exchange transfusion according to the AAP guidelines
was an accepted criterion as a definition of severe hyper-
bilirubinemia. The study population included inborn infants
diagnosed with severe hyperbilirubinemia prior to discharge
or rehospitalized following discharge from the birth facil-
ities, and outborn infants transferred to our center for
treatment of hyperbilirubinemia. All parents signed a
mandatory written consent form. In each case, serum was
collected to evaluate blood group, direct Coombs’ test,
complete blood cell count, total and direct bilirubin,
thyroid-stimulating hormone, and G6PD activity. These as-
sessments were performed to rule out a differential diag-
nosis. G6PD activity was measured when the infants were
admitted to the NICU with severe hyperbilirubinemia. The
samples were obtained from venous blood. Exclusion
criteria were prematurity (<35 weeks), ABO in-
compatibility, direct Coombs’ test positivity, hemoglobin
level <12 g/dL, white blood cell count 25,000/mm3,
positive blood culture, congenital anomaly, maternal dia-
betes, infection, asphyxia, cephalohematoma, hypothy-
roidism, and metabolic diseases. Due to these criteria, 164
infants were excluded from the study, and the remaining
529 term and late preterm (35 weeks) infants (228 fe-
males, 301 males) who were diagnosed with severe hyper-
bilirubinemia were included in the study. The birth weight
and gestational age of each infant were obtained from birth
records. Postnatal age (hours) and body weight at admis-
sion, as well as type of feeding (breastfeeding, formula
feeding, or mixed feeding), were recorded. Data regarding
phototherapy start time (postnatal hours) and duration, as
well as exchange transfusion, were also recorded. All in-
fants received phototherapy, which continued until the
total serum bilirubin level decreased to more than 2 mg/dL
below the phototherapy starting threshold level. The pho-
totherapy equipment and the level of irradiance were the
same for all infants.
Bilirubin levels were measured by diazo reaction and
photometric monitoring (Roche/Hitachi Modular P; Roche
Diagnostics GmbH, Mannheim, Germany). G6PD activity was
measured by spectrophotometry (Kornberg and Horacker,
Lohr and Waller Trinity Biotech 345 UV, Dublin, Ireland).
The principle of the test is that, in the process of the
conversion of glucose-6-phosphate to 6-phosphogluconate,
a reaction catalyzed by G6PD, NADP is reduced to NADPH.
The amount of NADPH produced is an index of G6PD ac-
tivity. Formation of NADPH is measured over a set period of
Figure 1 Correlation between G6PD activity and bilirubin
levels.
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same sample, and G6PD activity was recorded as U/g Hb.
G6PD activity is considered normal at 4.6e13.5 U/g Hb in
our institution.
SPSS for Windows (version 15.0; SPSS Inc., Chicago, IL,
USA) was used for statistical evaluation. Data are expressed
as mean  standard deviation (SD). The data were statis-
tically analyzed by descriptive statistics, using the Student
t test. Partial correlation analysis was used to assess the
relationship between G6PD activity and total bilirubin
levels. Hemoglobin, hematocrit, and birth weight were
controlled for with correlation testing. Spearman’s rank
correlation was used to evaluate the relationship between
total phototherapy time and G6PD activity. We used G6PD
<12 U/g Hb in males and <16 U/g Hb in females as the cut-
off values for each sex. These values had 90% specificity
and 10% sensitivity for predicting longer phototherapy time.
The ManneWhitney U test was used to assess the difference
in G6PD levels between the groups in terms of exchange
transfusion requirement. Because of the strong relationship
between breastfeeding and hyperbilirubinemia, we
analyzed breastfed infants separately.
3. Results
Thedescriptive data of the babies are summarized in Table 1.
Gestational age, age at the start of phototherapy, and per-
centage of distribution by feeding type are similar in male
and female infants. Only birth weight was different e the
males had higher birth weights than the females (pZ 0.001).
All infants in this study had severe hyperbilirubinemia, and
all received phototherapy. Breastfeeding, formula, and
mixed feeding rates were 72.2%, 6.4%, and 21.4%, respec-
tively. We did not advise interruption of breastfeeding.
There was a significant correlation between bilirubin levels
and G6PD activity in females (rZ 0.215, pZ 0.006), but not
in males (r Z 0.068, p Z 0.288). There was a significant
correlation between bilirubin level and G6PD activity in the
group of patients who started phototherapy after 72 hours
(females: r Z 0.270, p Z 0.001; males: r Z 0.139,
pZ 0.049) when controlled for birth weight and hemoglobin
and hematocrit levels (Figure 1). Phototherapy was started
after 72 hours in 237 males and 179 females.
A negative correlation was found between the duration
of the phototherapy and G6PD activity in the group ofTable 1 Demographic features of female and male newborns.
No. of patients Female
228 (43)
Gestational age (wk) 38.82  1.62
38.06e39.04
Age at the start of phototherapy (h) 128.36  59.
120.41e136.3
Birth weight (g) 3049.86  51
2980.88e311
Breastfed 160 (70.2)
Formula-fed 15 (6.6)
Breastfed and formula-fed 53 (23.2)
Data are presented as n (%) or mean  SD, 95% CI.patients who started phototherapy after 72 hours (females:
r Z 0.301, p Z 0.001; males: r Z 0.157, p Z 0.018).
This association is shown in Figure 2.
In this study, the female neonates with G6PD levels
<16 U/g Hb required more phototherapy time compared
with the female neonates with G6PD levels 16 U/g Hb
(p < 0.0001). The male neonates with G6PD levels <12 U/g
Hb required more phototherapy time compared with the
male neonates with G6PD levels 12 U/g Hb (p < 0.0001;
Table 2). When we analyzed only breastfed infants, we
observed a similar significant difference in both sexes
(p Z 0.001; Table 3).
Exchange transfusions were performed on 33 infants.
G6PD activity (10.22  5.98 U/g Hb) was significantly lower
in the infants who underwent exchange transfusions than in
those treated with phototherapy alone (14.12  4.92 U/g
Hb; p Z 0.009).
Three male infants developed kernicterus; their G6PD
levels were 12.8 U/g Hb, 9.4 U/g Hb, and 0.06 U/g Hb.
4. Discussion
Based on our analysis, we found a significant correlation
between bilirubin levels and G6PD activity in infants of bothMale
301 (57)
p
38.96  1.53
38.79e39.14
0.38
28
1
134.94  70.65
126.79e143.09
0.157
4.37
8.84
3275.57  515.11
3215.79e3335.34
<0.0001
222 (73.8) 0.63
19 (6.3)
60 (19.9)
Figure 2 The relationship between G6PD activity and pho-
totherapy duration.
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activity (males <12 U/g Hb; females <16 U/g Hb) who had
severe hyperbilirubinemia underwent a longer period of
phototherapy.
Owing to the wide distribution of G6PD activity and the
difficulties in diagnosing G6PD-deficient female infants, we
believe that only one cut-off level is not appropriate to
explain the relationship between G6PD activity and
hyperbilirubinemia.
Studies on G6PD deficiency indicate that infants with
G6PD deficiency have higher rates of hemolysis, a higher
prevalence of hyperbilirubinemia, and higher rates of
phototherapy treatment than those with normal G6PD lev-
els.18e20 In a study of 757 male and 326 female newborns
with G6PD deficiency, Weng et al21 found that G6PD activity
in G6PD-deficient male newborns with hyperbilirubinemia
was significantly lower than that of newborns without
hyperbilirubinemia. However, no significant difference was
shown between G6PD-deficient female newborns with
hyperbilirubinemia and those without hyperbilirubinemia.
There are conflicting views in the literature regarding the
association between hyperbilirubinemia and enzyme ac-
tivity. Kaplan et al22 compared enzyme activity between
male infants with and without hyperbilirubinemia. The
study included 64 male infants with G6PD deficiency and
436 male infants with normal enzyme activity; the re-
searchers found no association between hyperbilirubinemia
and enzyme activity among G6PD-deficient neonates. By
contrast, infants who developed hyperbilirubinemia with a
normal G6PD level had slightly higher enzyme activity than
those without hyperbilirubinemia. Another study of male
infants with G6PD deficiency showed no significantTable 2 G6PD activity, bilirubin levels, and phototherapy time
Male (n Z 301) G6PD <12 U/g Hb (n Z 86)
Phototherapy time (h) 45.6  20.5
Female (n Z 228) G6PD <16 U/g Hb (n Z 126)
Phototherapy time (h) 47.1  23.7
Data are presented as mean  SD.decrease in enzyme activity between those with and
without hyperbilirubinemia.23 In two studies, Kaplan
et al22,24 reported that there was no correlation between
G6PD activity and total bilirubin levels in G6PD-deficient
male newborns. We investigated the relationship between
G6PD activity and hyperbilirubinemia severity without
evaluating normal or deficient G6PD levels in severe
hyperbilirubinemic infants, and we found a significant
negative correlation between total bilirubin levels and
enzyme activity. In studies involving G6PD deficiency and
neonatal hyperbilirubinemia, the risk of developing hyper-
bilirubinemia is usually comparable in G6PD-deficient and
normal male newborns. Some studies have shown no asso-
ciation between G6PD-deficient individuals with low or high
enzyme activity and the severity and incidence of hyper-
bilirubinemia; however, female newborns were excluded
from these studies.22,24
Owing to the wide range of G6PD activity and the diffi-
culties in diagnosing G6PD deficiency in female infants, we
conclude that only one cut-off level is not appropriate to
explain the relationship between G6PD activity and hyper-
bilirubinemia. In a recent study, the researchers proposed
that the range of borderline G6PD activity should be
2e10 U/g Hb rather than the currently accepted range of
2e7 U/g Hb.25 Infants with low and borderline G6PD activity
were more likely to require phototherapy and to be
referred for exacerbation of jaundice. Other studies sup-
port the expansion of the upper limit of intermediate range
G6PD activity.26,27 It is evident that there is no consensus
regarding the level of G6PD activity that results in the risk
of neonatal hyperbilirubinemia. However, the tendency is
to push the borderline higher. This is a view we also
embrace, based on the findings of our study, which supports
the overall correlation between G6PD activity and the
severity of hyperbilirubinemia.
When compared with adults, low levels of glutathione/
glutathione disulfide in newborns have shown that new-
borns have higher oxidative stress,15 indicating that eryth-
rocytes are exposed to increased free radicals after
delivery.28 The G6PD is necessary for the regeneration of
the reduced form of glutathione, which is essential for the
reduction of hydrogen peroxide and oxygen radicals and for
the maintenance of hemoglobin and other hemoglobin
proteins in the reduced state.4,29,30 Under normal condi-
tions, maintenance of this pathway protects erythrocytes
from oxidative stress; however, reduced G6PD levels could
lead to failure of this system and hemolysis. Particularly in
the neonatal period, when oxidative stress is higher and the
antioxidant system is diminished,14,15 this situation could
exacerbate the severity of hyperbilirubinemia. A study
measuring heme destruction by corrected end tidal carbon
monoxide indicated that heme catabolism might play an
important role in the development of hyperbilirubinemia.
G6PD 12 U/g Hb (n Z 215) p
41.6  23.5 <0.0001
G6PD 16 U/g Hb (n Z 102) p
36.4  19.3 <0.0001
Table 3 G6PD activity, bilirubin levels, and phototherapy time in infants who were breastfed only.
Only breastfed male (n Z 222) G6PD <12 U/g Hb (n Z 77) G6PD 12 U/g Hb (n Z 145) p
Phototherapy time (h) 53.9  30.1 40.3  18.1 0.001
Only breastfed female (n Z 160) G6PD <16 U/g Hb (n Z 97) G6PD 16 U/g Hb (n Z 63) p
Phototherapy time (h) 48.5  24.4 36.0  20.5 0.001
Data are presented as mean  SD.
206 H. Kilicdag et alduring the first 4 days of life.24 According to that study, the
association between neonatal hyperbilirubinemia and lower
G6PD activity might be related to moderate hemolysis.24
It is difficult to demonstrate mild hemolysis with routine
laboratory evaluations. No decrease was detected in the
hemoglobin levels of these patients, nor was there an in-
crease in the reticulocyte count or hemolysis in peripheral
blood samples. In the first days of life, bilirubin conjugation
and elimination are markedly low, and minor increments of
bilirubin production could contribute to the development of
severe hyperbilirubinemia.31
Another important point which was emphasized in our
study was phototherapy duration, which was significantly
longer when G6PD activity decreased, in both male and
female newborns. Viewed from this perspective, this
study, to our knowledge, seems to be the first in the
literature to compare overall G6PD activity and photo-
therapy duration. We found that when G6PD activity was
<12 U/g Hb in males and <16 U/g Hb in females, there was
a strong association between prolonged phototherapy time
and G6PD activity.
Previous reports have shown that G6PD deficiency leads
to early occurrence of hyperbilirubinemia, which requires
phototherapy or exchange transfusion.32,33 In different
populations, this could be concomitant with kernicterus or
death.34,35 In our study, G6PD activity in the group treated
with exchange transfusion was significantly lower. Three
male infants whose G6PD levels were 12.8 U/g Hb, 9.4 U/g
Hb, and 0.06 U/g Hb developed kernicterus during the study
period.
Breastfeeding, G6PD deficiency, and ABO incompatibility
are common etiologies in severe hyperbilirubinemia.36
Jaundice in breastfed infants is commonly of undeter-
mined etiology, and breastfed infants have higher bilirubin
levels than formula-fed infants.37 To demonstrate the ef-
fect of G6PD activity on severe hyperbilirubinemia, we
analyzed breastfed infants separately, and our analysis
indicated a statistically significant relationship between
prolonged phototherapy time and G6PD activity. Although
we found a significant correlation between G6PD activity
and severity of hyperbilirubinemia in female newborns who
were fed mother’s milk alone, we did not find this corre-
lation in male newborns. Breast milk is a modifier for
selected genotypes,37,38 and thus it can potentially affect
development of severe obvious neonatal jaundice.
The increase in hyperbilirubinemia severity when G6PD
activity decreases may be related to physiological features.
The baby moves from the intrauterine environment, where
partial oxygen pressure is 20e25 mmHg, to the extrauterine
environment, where partial oxygen pressure is 100 mmHg.
This increase in oxygen pressure may lead to increased
production of reactive oxygen molecules. In addition, a
lower antioxidant capacity, coupled with the stress of thedelivery, may stimulate hypoxia and oxidative stress.6
Therefore, newborns need even higher G6PD levels to
combat higher oxidative stress.15
In a study comparing hyperbilirubinemia in 64 male
G6PD-deficient newborns and 436 normal male infants, the
G6PD-deficient group had a phototherapy requirement
3.54-fold higher than that of the other group.24 In another
study, which compared 24 neonates with G6PD deficiency
and indirect hyperbilirubinemia with 624 term neonates
with normal G6PD and indirect hyperbilirubinemia accord-
ing to serum bilirubin on admission, maximum serum bili-
rubin level and the need for exchange transfusion were
higher (33.3% vs. 15%) in the G6PD-deficient group.20
Katar39 reported on 56 male infants with hyper-
bilirubinemia who received exchange transfusions, 10 (18%)
of whom were G6PD deficient. The increase in necessity of
exchange transfusion and phototherapy duration in the
G6PD-deficient group is due to the increased severity of
hyperbilirubinemia. G6PD deficiency should be considered
in neonates who develop hyperbilirubinemia within the 2nd
day of life, with two peaks seen on Day 4 and Day 7.33 In our
study, most of the infants needed phototherapy after 72
hours of life.
In conclusion, the results of this study demonstrate that
there is a significant correlation between the severity of
hyperbilirubinemia and G6PD activity, regardless of G6PD
level (deficient/normal), in both male and female infants.
Breastfed females exhibited a significant correlation be-
tween G6PD activity and hyperbilirubinemia severity.
Another important aspect of this study was the duration of
phototherapy, which significantly increased as G6PD activ-
ity decreased, in both male and female newborns.
Routine monitoring of G6PD levels in hyperbilirubinemic
neonates is very important for providing proper medical
management to prevent bilirubin-induced neurological
dysfunction. Appropriate identification of G6PD (<12 U/g Hb
for male infants and <16 U/g Hb for female infants) raises
awareness of the severity of this condition, as well as the
necessity for immediate care of severe hyperbilirubinemic
infants.
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